Background:Cancer involves uncontrolled cell growth due to genetic mutations. Tumors
can form when CDK6, a gene essential for controlling cell growth, isn't working correctly.
Researchers are investigating drugs that inhibit CDK6; some of them appear promising. Nevertheless,
CDK6 is advantageous and harmful to cancer because it controls other cellular processes. By
inhibiting CDK6 and CDK4, CDK4/6 inhibitors offer a novel therapeutic strategy that stops cell
proliferation. The study investigates the function of CDK6 in cancer, the difficulties in targeting
CDK6, and possible remedies.Objective:Scientists have developed drugs designed to block CDK6 and prevent it from altering
other proteins. These drugs, also known as CDK6 inhibitors, help treat cancer. Finding the best
drugs for CDK6 is still tricky, though. The drugs' selectivity, potency, and cost are some difficulties.
These factors depend on CDK6's structure and interactions with other proteins. The structure
of CDK6 and how it influences its function and regulation are explained in this review. It also describes
CDK6's function in cancer and its interaction with other molecules and proteins, which is
crucial for cell division. This review also discusses the present and upcoming therapies that target
CDK6, as well as how CDK6 interacts with drugs that block it.Conclusion:This review presents the structure, current research, and overview of CDK6. It also
reviews the role of CDK6 in cancer, function, and regulation. Additionally, it explores its role in
cancer signaling networks and its interaction with CDK6 inhibitors. Lastly, it discusses the current
status and prospects of therapies targeting CDK6.
